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INTRODUCTION
Connective tissue diseases (CTDs) are characterized by im-
mune system dysregulation, circulating autoantibodies and
multisystem disease. Diagnosis is made using both clinical and
serological features. Renal involvement—manifesting as renal
failure or urine dipstick abnormalities—may be the presenting
feature of CTD. Renal and general physicians need to have a
good understanding of how serological testing can help in the
diagnosis of CTD.
Here we consider how anti-nuclear antibody (ANA) and ex-
tractable nuclear antigen (ENA) testing can aid the diagnosis of
CTD in patients with renal disease. We review how these assays
are performed and the principles of serological testing. We
summarize the clinical features, renal pathology and diagnostic
performance of ANA and ENA testing in a range of CTDs. (We
do not discuss lupus nephritis, which is comprehensively cov-
ered elsewhere in the literature.)
How are ANA and ENA assays performed?
ANAs are directed towards components of the cell nucleus.
They are detected by indirect immunofluorescence using the
human epidermoid carcinoma (HEp-2) cell line. HEp-2 cells,
with large nuclei containing many autoantigens, are well suited
for the detection of autoantibodies. Patient serum is incubated
with the cells before a fluorescent antibody to human immuno-
globulin is added. Samples are tested first at a screening dilution
(e.g. 1:80) and, if positive, are sequentially diluted until fewer
than half the cells are positively stained. This dilution is reported
to reflect the strength of ANA binding present in the serum.
Weakly positive ANA titres are common and are often not
clinically significant [1]. In addition to the titre, most laborato-
ries report the staining pattern of the antibody, for example,
homogeneous, speckled, centromere or nucleolar. This reflects
different nuclear proteins to which the antibody has bound
(Table 1).
Specific nuclear antigens are associated with different CTDs.
Such antigens were historically removed from the nucleus using
salt extraction, giving the name ENAs, but are now commonly
measured using a solid-phase enzyme-linked immunosorbent
assay technique. These include Sjo¨gren’s syndrome–related an-
tigen A (SSA; also known as Ro), Sjo¨gren’s syndrome–related
antigen B (SSB; also known as La), Smith (Sm), topoisomerase
1, ribonucleic acid (RNA) polymerase III, Jo-1 and U1 ribonu-
cleic protein (U1RNP). The antigen panel used for an ENA
screen varies between laboratories. For specific clinical ques-
tions or in the case of diagnostic uncertainty, it can be helpful to
discuss extended screening with a local immunologist.
Principles of test interpretation
With any test, it is important to understand the sensitivity
and specificity and positive and negative predictive values (PPV
and NPV, respectively). Sensitivity and specificity are often gen-
erated from case–control studies and, depending on the clinical
characteristics and disease prevalence, it is possible to over-
estimate the PPV [2]. Furthermore, these are not necessarily in-
tuitive concepts, and clinicians often overestimate the chance of
disease with a positive test result [3].
The diseases we discuss have a low prevalence and the PPV
of ANA is poor if applied to the general population. Testing
only adds value in the presence of a reasonably high pre-test
probability, and the results need to be carefully interpreted with
knowledge of the clinical context.
In the remainder of this article we consider individual
CTDs. We summarize the salient clinical features (i.e. features
that might prompt autoantibody testing) and then discuss the
diagnostic performance of ENA tests in that disease.
Sjo¨gren’s syndrome
Sjo¨gren’s syndrome is characterized by B-cell activation
and lymphocytic infiltration of exocrine glands, causing ker-
atoconjunctivitis sicca and xerostomia. Renal involvement
occurs in up to 20% of patients and can predate the clinical
diagnosis in 30%. In 75% of cases there is an acute or
chronic tubulointerstitial nephritis with a CD4þ T-cell
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infiltrate. There may be also tubular defects, typically distal
hypokalaemic renal tubular acidosis. Proximal tubular dys-
function can occur, but rarely as full-blown Fanconi syn-
drome. The remaining 25% of patients have glomerular
disease, most commonly immune complex–mediated mem-
branoproliferative glomerulonephritis (MPGN) [4].
The most common ENAs are anti-SSA (in 50–70% of
patients) and anti-SSB (in 25–40%). While it is possible to have
anti-SSA but negative anti-SSB, the converse is rare. Their pres-
ence correlates to diagnosis at a younger age, longer disease du-
ration and more severe exocrine gland involvement. Anti-SSA
immunoglobulin G can cross the placenta and cause neonatal
heart block. While anti-SSA can also be found in other CTDs
such as systemic lupus erythematosus (SLE), anti-SSB is more
specific for Sjo¨gren’s syndrome (Table 1) [5].
Systemic sclerosis
Systemic sclerosis (SSc) is characterized by an overproduc-
tion of extracellular matrix proteins and collagen resulting in
tissue fibrosis. Vascular proliferation leads to an obliterative
vasculopathy. Features include Raynaud’s phenomenon, pul-
monary fibrosis, pulmonary hypertension, oesophageal dysmo-
tility and scleroderma renal crisis. It is classified as diffuse
cutaneous SSc (dcSSc; skin involvement proximal to the elbows
and knees) or limited cutaneous SSc [lcSSc; distal skin involve-
ment, also known as CREST (calcinosis, Raynaud’s phenome-
non, esophageal dysmotility, sclerodactyly, and telangiectasia)
syndrome].
Scleroderma renal crisis develops in 5–10% of patients with
dcSSc. This is defined by new-onset accelerated hypertension
and rapidly progressive renal impairment (with microangio-
pathic haemolytic anaemia in 50% of patients). Renal biopsy
shows a thrombotic microangiopathy with mucinoid
hyperplasia and fibrinoid necrosis that progresses to a prolifera-
tive arteriolopathy with characteristic onion-skin appearance in
arcuate and interlobular arteries.
Patients with SSc may develop other renal lesions, including
penicillamine-related membranous nephropathy, scleroderma-
associated vasculopathy and myeloperoxidase-positive
vasculitis [6].
The predominant ENAs are anti-centromere and anti-Th/
To in lcSSc and anti-topoisomerase 1 and anti-RNA polymer-
ase III in dcSSc. Anti-U1RNP, U3RNP and PM-Scl are found in
SSc overlap syndromes. Anti-centromere is specific (97%) for
SSc when tested in patients with other CTDs and has a PPV of
89.5%. Their presence is associated with peripheral arterial dis-
ease and pulmonary arterial hypertension. Anti-Th/To has
been less widely studied and the sensitivity and specificity are
not accurately known, but they are present in 5% of patients
and associated with pulmonary hypertension and fibrosis [7].
Anti-topoisomerase 1 is highly specific (99.5%), with an excel-
lent PPV of 98% but a lower sensitivity (26%). It is associated
with cardiac involvement and pulmonary fibrosis. Anti-RNA
polymerase III has the strongest association with scleroderma
renal crisis, found in 50% of patients developing this
complication [8].
Polymyositis and dermatomyositis
These are inflammatory disorders of skeletal muscle, pre-
senting with symmetrical proximal muscle weakness.
Dermatomyositis occurs as a result of a complement-mediated
microangiopathy and can be associated with underlying malig-
nancy or an overlap with mixed connective tissue disorder.
Polymyositis is characterized by an inflammatory infiltrate of
CD8þ T cells in muscle fibres [9]. Renal manifestations are
most commonly acute kidney injury secondary to
Table 1. Prevalence and associations of antinuclear autoantibodies in CTDs
CTD Autoantibody Prevalence in
disease (%)
Sensitivity
(%)
Specificity
(%)
Staining pattern Antibody association
Sjo¨gren’s
syndrome
Anti-SSA
Anti-SSB
50–70
25–40
8–70
16–40
87
94
Speckled nuclear
Speckled nuclear
Neonatal heart block
Limited cutaneous
scleroderma
Anti-centromere
Anti-Th/To
Anti-U1RNP
30
5
5
31 97 Centromere
Nucleolar
Speckled nuclear
Pulmonary hypertension, peripheral
vascular disease
Pulmonary ﬁbrosis
Mixed connective tissue disorder
Diffuse cutaneous
scleroderma
Anti-topoisomerase 1
(anti-Scl-70)
Anti-RNA polymerase III
Anti-U3RNP (ﬁbrillarin)
30
15
5
26
12
99.5
96
Various
Nucleolar
Nucleolar
Pulmonary ﬁbrosis, cardiac
involvement
Greatest association with sclero-
derma renal crisis (in 52% of
patients)
More common in African Americans
and males; pulmonary hyperten-
sion and skeletal muscle
involvement
Mixed connective
tissue disorder
Anti-U1RNP 100 Speckled nuclear Usually required for diagnosis
Polymyositis
Dermatomyositis
Anti-Jo-1 20 Cytoplasmic Polymyositis> dermatomyositis
Anti-synthetase syndrome: myositis,
idiopathic interstitial lung disease,
arthritis and Raynaud’s
phenomenon
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rhabdomyolysis and myoglobinuria. Chronic glomerulonephri-
tis can occur. MPGN is most commonly described in polymyo-
sitis and membranous nephropathy in dermatomyositis [10].
Anti-Jo-1 is an antibody against histidyl-tRNA synthetase
and is found in 20% of patients [9]. It can also be found in
patients with interstitial lung disease without myositis.
Mixed connective tissue disorder
Mixed connective tissue disorder has overlapping features of
SLE, SSc and dermatomyositis. Anti-U1RNP is suggestive of
the diagnosis. Renal involvement occurs less frequently than in
other disorders. The most common lesion is membranous
nephropathy [7]. As mixed CTD can evolve into SLE or SSc,
patients can develop lupus nephritis or scleroderma-related
nephropathy.
CONCLUSIONS
Renal involvement is common in CTDs and causes a range of
glomerular, tubulointerstitial and vascular pathologies.
Autoantibody testing can play an important diagnostic role in
patients with multisystem symptoms with renal impairment or
dipstick abnormalities. However, their effective clinical utility
depends on a reasonably high working pre-test probability of
disease, as serological tests are not generally well-performing
screening tools in wider populations.
Close liaison with the immunology laboratory can be helpful
in evaluating patients whose clinical picture and serological test
results are discordant. In some cases, testing for extended auto-
antibody panels is helpful in reaching a firmer diagnosis. In
other cases, alternative diagnoses can lead to unexpected sero-
logical test results.
We summarize the diagnostic performance of ANA and
ENA tests in Table 1.
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